Successful treatment of hand and foot psoriasis with infliximab

Dermatology Online Journal

Volumn 16, Issue 7, 2010, Pages

  Di Lernia, Vito ^a   Guareschi, Elisa ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADL DISABILITY; ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HYPERKERATOSIS; MALE; MONOTHERAPY; PHYSICAL EXAMINATION; PSORIASIS SEVERITY INDEX; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RECURRENT DISEASE; SKIN DEFECT; SKIN FISSURE; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA;

EID: 77958138182     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009 Jun; 60(6):1024-31. [PubMed]
2. Asumalahti K, Ameen M, Suomela S et al. Genetic analysis of PSOR1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003 Apr; 120(4):627-32. [PubMed]
3. Marsland AM, Chalmers RJ, Hollis S et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006 Jan 25; (1):CD001433. [PubMed]
4. Lassus A, Geiger JM. Acitetin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol 1988 Dec; 119(6):755-9. [PubMed]
5. Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 1991 Jun; 124(6):581-4. [PubMed]
6. Matsunami E, Takashima A, Mizuno N et al. Topical PUVA, etretinate, and combined PUVA and etretinate for palmoplantar pustulosis: comparison of therapeutic efficacy and the influences of tonsillar and dental focal infections. J Dermatol 1990; Feb; 17(2):92-6. [PubMed]
7. Fretzin S, Crowley J, Jones L et al. Successful treatment of hand and foot psoriasis with efalizumab therapy. J Drugs Dermatol 2006 Oct; 5(9): 838-46. [PubMed]
8. Leonardi C, Sobell J, Sofen H et al. Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot psoriasis. J Am Acad Dermatol 2007; 56(2): AB48.
9. Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, Poulin-Costello CM, Nigen S. Etanercept in the treatment of pustolosis palmoplantaris. J Drugs Dermatol 2008 Oct; 7(10): 940-6. [PubMed]
10. Weinberg JM. Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis 2003 Nov; 72(5):396-8. [PubMed]
11. Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004; 150:1009-12.
12. Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to anti-tumor necrosis factor alpha antibody (infliximab). Br J Dermatol 2004; 150: 367.
13. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis von Zumbusch type. Int J Dermatol 2002; 41:449-52.
14. Wozel G, Vitéz L. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Derm Venereol 2008; 88: 169-70.
15. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004; 3: 77-9.